The 9th IAS Conference on HIV Science (IAS 2017) is going back to basics, with the largest-ever selection of abstracts from the field of basic science. This year we return to Paris, the city renowned for the co-discovery of HIV and pioneering scientific research. Highlights will include:
- New understanding from a novel barcoded virus of how the latent HIV reservoir is reactivated following treatment interruption
- Implications from a study of a subset of elite controllers who maintain an undetectable viral load without antiretroviral treatment (ART)
- Latest insights on the critical steps of the viral entry process
- Evidence on the role of lymph nodes in the development of neutralizing antibodies after immunization
- Novel strategies to interfere with the persistence of the viral reservoir
- Findings from a post-mortem study on HIV in the brain, and its association with neurocognition
- Outcomes from immunotherapeutic interventions to control or “functionally cure” HIV
- Analysis of HIV sequences to track the evolution and epidemiology of the virus within populations and countries
Broadly neutralizing antibodies against HIV
This symposium addresses scientists and clinicians concerned with the feasibility, applicability and effectiveness of broadly neutralizing antibodies to prevent HIV infection or establish long-term control of viral replication.
Advances in HIV transmission and regulation of replication
This symposium focuses on the impact of host genetic and biological variations, viral pre-adaption and restriction factors on HIV acquisition and replication in both primates and humans.
This symposium focuses on the role of the major actors of adaptive and innate immunity in the fight against HIV: IFN type I response, NK cells, B cells and polyfunctional antibodies, and CD4+ and CD8+ T cells.
This workshop, aimed at researchers and scientists concerned with technological developments and applications necessary to decipher the precise mechanisms underlying HIV pathogenesis, focuses on Nex-Gen technologies applied to HIV basic science.
This session focuses on the critical role of vaccine development in the fight against HIV. It is addressed to all scientists and clinicians concerned with the genesis of novel HIV vaccine candidates towards their efficacy in clinical trials.
Residual disease and immune activation/inflammation on ART
This workshop focuses on the role of persistent immune activation and inflammation in the residual disease of HIV-infected patients receiving ART, including the role of the microbiome, interventions to reduce systemic immune activation, immune ageing and co-morbidities in HIV-infected individuals.
Primary HIV infection and early treatment
This bridging session provides insights into the early events following HIV primary infection and how treatment initiation at this stage may promote control of HIV and prevent the establishment of chronic infection.
Plenary sessions on basic science
Professor Yves Lévy on harnessing the immune system to prevent and control HIV infection; virologist Paul Bieniasz on HIV restriction factors from bench to bedside; Professor Tasuku Honjo on PD-1 blockade immunotherapy against cancer and infectious diseases; Professor Fabien Zoulim on challenges and novel approaches to cure hepatitis B infection.